Summit Therapeutics Inc. SMMT
We take great care to ensure that the data presented and summarized in this overview for Summit Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SMMT
View all-
Baker Bros. Advisors LP New York, NY24.4MShares$436 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$196 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$141 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$97.2 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$62 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.1MShares$55.4 Million0.01% of portfolio
-
Charles Schwab Investment Management Inc San Francisco, CA1.43MShares$25.6 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.22MShares$21.8 Million0.01% of portfolio
-
Abrdn PLC1.14MShares$20.3 Million0.05% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.08MShares$19.4 Million1.93% of portfolio
Latest Institutional Activity in SMMT
Top Purchases
Top Sells
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Insider Transactions at SMMT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 03
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
315,681
+3.0%
|
$315,681
$1.58 P/Share
|
|
Sep 11
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
44,052
+0.18%
|
$969,144
$22.7 P/Share
|
|
Sep 11
2024
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,325,991
+0.6%
|
$73,171,802
$22.7 P/Share
|
|
Sep 11
2024
|
Jeff Huber Director |
BUY
Grant, award, or other acquisition
|
Indirect |
44,052
+50.0%
|
$969,144
$22.7 P/Share
|
|
Sep 11
2024
|
Bhaskar Anand Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,026
+14.35%
|
$484,572
$22.7 P/Share
|
|
Sep 11
2024
|
Manmeet Singh Soni COO and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
44,052
+1.44%
|
$969,144
$22.7 P/Share
|
|
Mar 27
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
54,321
+14.35%
|
$162,963
$3.72 P/Share
|
|
Mar 27
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
26,000
+4.75%
|
$78,000
$3.72 P/Share
|
|
Mar 26
2024
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
100,000
+21.98%
|
$300,000
$3.75 P/Share
|
|
Mar 26
2024
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
30,000
+50.0%
|
$90,000
$3.75 P/Share
|
|
Dec 13
2023
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
20,400
+3.73%
|
$40,800
$2.16 P/Share
|
|
Dec 12
2023
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.0%
|
$10,000
$2.07 P/Share
|
|
Dec 11
2023
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Indirect |
315,681
+1.25%
|
$315,681
$1.58 P/Share
|
|
Dec 11
2023
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Exercise of in-the-money or at-the-money derivatives securities
|
Direct |
489,814
+50.0%
|
$489,814
$1.44 P/Share
|
|
Oct 13
2023
|
Manmeet Singh Soni COO and CFO |
BUY
Open market or private purchase
|
Direct |
2,976,190
+50.0%
|
$2,976,190
$1.68 P/Share
|
|
Mar 08
2023
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
7,553,301
+40.57%
|
$7,553,301
$1.05 P/Share
|
|
Mar 08
2023
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
15,973,743
+40.57%
|
$15,973,743
$1.05 P/Share
|
|
Mar 07
2023
|
Ankur Dhingra Chief Financial Officer |
BUY
Open market or private purchase
|
Indirect |
196,362
+45.57%
|
$196,362
$1.05 P/Share
|
|
Mar 06
2023
|
Robert W Duggan Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
376,489,880
+40.53%
|
$376,489,880
$1.05 P/Share
|
|
Dec 06
2022
|
Maky Zanganeh Co-Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
373,857
+3.31%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 3.48M shares |
|---|---|
| Open market or private purchase | 210K shares |
| Exercise of in-the-money or at-the-money derivatives securities | 316K shares |